|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: Ceredase and pregnancyFrom: afish04@emory.eduWed May 15 08:55:39 1996
Gary, The recombinant therapy supply has been somewhat low recently and restricted to those who have developed antibodies or who are on experimental protocol. Thus, you may want to look into this. Emory does not do the mutational anaysis but Mount Sinai and Cincinnatti do. Their telephone numbers and contact persons respectively are (212)241-9196 ( Gregory Pastores, MD) and (513) 559-7290 (Gregory Grabowski, MD). I am sure that they take Medicaid. In GA they pay for the mutational analysis. This may be important for genotype/phenotype correlation and who knows, pregnancy outcome with the cocurrent treatment with Ceredase. If you want to contact the person at USC and their experience with Ceredase therapy in pregnancy, her name is Joan Esplin,MD at 800 USC 7770. We have a couple of protocols that we are doing with our patients. If your patient is interested, you can contact Karen Grinzard at (404) 727-5731. It sounds like a nice system that you have there, esp. for obtaining CRL/FHT for the first trimester. This removes the eversolasting problem of dating criteria and you do your organ survey in the midsecond trimester. The best of both worlds...congragulations. Allan Fisher, MD
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Mon Nov 2 05:18:26 2009 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.